Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Procore Technologies Seeing Early Signs of AI Adoption, Oppenheimer Says

Procore Technologies Seeing Early Signs of AI Adoption, Oppenheimer Says

MT newswireMT newswire2026/10/23 17:10
01:10 PM EDT, 10/23/2026 (MT Newswires) -- Procore Technologies (PCOR) is seeing early signs of AI adoption, with its Procore AI Starter Pack providing a low-friction entry point for customers, Oppenheimer said in a Friday research report. The demand environment appears healthy despite a mixed construction macroeconomic backdrop, with labor shortages the main concern affecting customers, according to the note. Oppenheimer also highlighted strong customer enthusiasm for DroneDeploy. It said the integration could strengthen Procore's AI-powered platform and enable cross-selling opportunities. The company's AI partnerships could also broaden its relevance across pre-construction, jobsite execution, and owner operations, the note added. Oppenheimer has a perform rating on Procore Technologies. The company's shares were up 1.6% in Friday afternoon trading. Price: 63.27, Change: +0.98, Percent Change: +1.57
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56